TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial

A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational ...

Healio AI Introduces CME Credit for Clinical Search Activity

In partnership with its sister company, Vindico Medical Education, Healio AI now offers Internet Point of Care (PoC) AMA PRA Category 1 Credits™, allowing physicians and other health care ...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the ...
Nasdaq

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...
Morningstar

Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025

CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I), ...
Business Wire

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...
Nasdaq

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant ...
Business Wire

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear ...
Applied Clinical Trials Online

SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations

Miriam Dervan, founder & CEO of mdgroup, explains how treating patient experience as a strategic investment—rather than a ...
The American Journal of Managed Care

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

Tarlatamab showed promising antitumor activity in heavily pretreated SCLC patients, including those with untreated brain metastases. Real-world data indicated higher rates of CRS and ICANS compared to ...
Morningstar

Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers

CAMBRIDGE, Mass., Oct. 31, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation ...
FierceBiotech

French biotech discontinues all clinical activities, shuts down US site

Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” candidate designed to treat recurrent solid tumors. The Paris-based biotech ...